Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 3 1

Status

Unknown 6Recruiting 5Withdrawn 4Completed 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 2Thoracic 1Other hematologic neoplasm 1

Conditions

Stomach Neoplasms 1MCRC 1Lymphopenia 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × Interventional × Thymalfasin × Clear all
NCT06461910 2026-03-03

Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Stomach Neoplasms

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting
52 enrolled

MCRC

NCT06584006 2024-09-19

Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors

The First Affiliated Hospital of Xiamen University

Phase 2 Recruiting
50 enrolled
Other hematologic neoplasm

Lymphopenia, Hematologic Neoplasms

NCT06598839 2024-09-19

Immuno-effect of Tα1 for Stage I NSCLC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase NA Recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05086614 2021-10-21

Thymosin-alpha 1 for Adjuvant Treatment After Radical Resection of High-risk Stage II and III Colorectal Cancer

Fudan University

Phase 3 Recruiting
2,500 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡